RxDoctor Payments DataLook up a doctor →

Patrick Pavwoski, DO

Neurology · Muskegon, MINPI 1073953881

Payments from drug & device makers

$241,892in general payments, 2019–2025

Across 950 payments — averaging $254.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$166K
  • Biogen$37K
  • Biohaven Pharmaceuticals, Inc.$14K
  • Pfizer$6K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • EMD Serono, Inc.$3K
  • plus $11K from 49 others

What the payments were for

  • Consulting fees$9,4074%
  • Speaking & faculty fees$196,37581%
  • Travel & lodging$14,7106%
  • Food & beverage$21,3959%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$241,892 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$63,903
Medicare patients
289
Services billed
1,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine16$96,351
UbrelvyUbrogepant62$86,938
Aimovig AutoinjectorErenumab-Aooe87$63,189
Nurtec OdtRimegepant Sulfate32$48,018
Emgality PenGalcanezumab-Gnlm31$20,305
NuedextaDextromethorphan Hbr/Quinidine12$18,526
NourianzIstradefylline11$18,413
QuliptaAtogepant18$17,468
Ajovy AutoinjectorFremanezumab-Vfrm14$13,252
EliquisApixaban11$6,342
Lacosamide65$4,854
Primidone65$3,980
Sumatriptan Succinate109$3,312
Levetiracetam104$3,001
Propranolol Hcl ErPropranolol Hcl99$2,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$166,184$104,40680 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$1,049$96,35116 claims
PfizerNurtec Odt, Eliquis$5,712$54,35943 claims
Avanir Pharmaceuticals, Inc.Nuedexta$79$18,52612 claims
Kyowa Kirin, Inc.Nourianz$152$18,41311 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$28$2,69619 claims
Upsher-smith Laboratories LLCTopiramate$215$1,04790 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.

Other neurology in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →